Aydin Huseynov, M.D., CFA

Dr. Aydin Huseynov is a Managing Director in the Healthcare Investment Banking Group at Ladenburg Thalmann. With a career spanning clinical medicine, corporate strategy, and Wall Street, he provides a multi-dimensional perspective on scientific rationale and healthcare valuation. His primary focus is helping biotechnology companies navigate the capital markets, advising management teams on strategic positioning, and leading the origination and execution of financing transactions to fund the development of innovative therapies.

Prior to his current role, Dr. Huseynov served as Managing Director and Senior Equity Research Analyst at Ladenburg Thalmann, and held senior equity research positions at The Benchmark Company and Oppenheimer & Co. His healthcare finance experience also includes investment banking at MTS Health Partners, where he focused on advisory and transactional execution within the biotech sector, and strategy consulting at Syneos Health Consulting.

Dr. Huseynov brings additional corporate perspective from his work as a strategist at Teva Pharmaceuticals, complemented by his foundational experience as a practicing physician and entrepreneur.

He holds an M.D. and an M.S. in International Economic Relations, as well as an MBA from The Fuqua School of Business at Duke University. He is a CFA Charterholder.